Recurrent Respiratory Papillomatosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: RCR004 MIFTS: 47	Recurrent Respiratory Papillomatosis Categories: Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Recurrent Respiratory Papillomatosis

MalaCards integrated aliases for Recurrent Respiratory Papillomatosis:

Name: Recurrent Respiratory Papillomatosis ⁴⁹ ⁵⁵ ⁶⁹

Juvenile-Onset Recurrent Respiratory Papillomatosis ⁴⁹

Adult-Onset Recurrent Respiratory Papillomatosis ⁴⁹

Respiratory Papillomatosis, Recurrent ⁴⁹

Laryngeal Papilloma, Recurrent ⁴⁹

Juvenile Laryngeal Papilloma ⁴⁹

Aorrp ⁴⁹

Jorrp ⁴⁹

Rrp ⁴⁹

Characteristics:

Orphanet epidemiological data:

⁵⁵

recurrent respiratory papillomatosis
Age of onset: Adolescent,Adult,Childhood;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁵

Rare respiratory diseases

External Ids:

Orphanet ⁵⁵ ORPHA60032

MESH via Orphanet ⁴² C535297

UMLS via Orphanet ⁷⁰ C1168198

UMLS ⁶⁹ C1168198

Sources

Summaries for Recurrent Respiratory Papillomatosis

NIH Rare Diseases : ⁴⁹ Recurrent respiratory papillomatosis (RRP) is a rare viral disease where tumors (papillomas) grow in the air passages leading from the nose and mouth into the lungs (respiratory tract). Although the tumors can grow anywhere in the respiratory tract, their presence in the larynx (voice box) causes the most frequent problems, a condition called laryngeal papillomatosis. The tumors may vary in size and grow very quickly. They often grow back even when removed. RRP is caused by two types of human papillomavirus (HPV), called HPV 6 and HPV 11. Last updated: 11/21/2011

MalaCards based summary : Recurrent Respiratory Papillomatosis, also known as juvenile-onset recurrent respiratory papillomatosis, is related to mumps and diabetes mellitus. An important gene associated with Recurrent Respiratory Papillomatosis is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Innate Immune System and GPCR Pathway. The drugs Cidofovir and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and t cells.

Sources

Related Diseases for Recurrent Respiratory Papillomatosis

Diseases related to Recurrent Respiratory Papillomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)

#	Related Disease	Score	Top Affiliating Genes
1	mumps	30.2	HLA-DRB1 IL2
2	diabetes mellitus	29.3	HLA-DQA1 HLA-DQB1 HLA-DRB1
3	laryngeal papillomatosis	11.1
4	limbic encephalitis with lgi1 antibodies	10.4	HLA-DQB1 HLA-DRB1
5	metal allergy	10.4	HLA-DQB1 HLA-DRB1
6	lichen planopilaris	10.3	HLA-DQB1 HLA-DRB1
7	type ii mixed cryoglobulinemia	10.3	HLA-DQB1 HLA-DRB1
8	idiopathic inflammatory myopathy	10.3	HLA-DQB1 HLA-DRB1
9	chronic beryllium disease	10.3	HLA-DQB1 HLA-DRB1
10	autoimmune pancreatitis	10.3	HLA-DQB1 HLA-DRB1
11	pityriasis rosea	10.3	HLA-DQB1 HLA-DRB1
12	lichen sclerosus	10.3	HLA-DQB1 HLA-DRB1
13	whipple disease	10.3	HLA-DQB1 HLA-DRB1
14	pediatric multiple sclerosis	10.3	HLA-DQB1 HLA-DRB1
15	osteonecrosis of the jaw	10.3	HLA-DQB1 HLA-DRB1
16	cystic echinococcosis	10.3	HLA-DQB1 HLA-DRB1
17	berylliosis	10.3	HLA-DRB1 IL2
18	peanut allergy	10.3	HLA-DQB1 HLA-DRB1
19	panuveitis	10.3	HLA-DQB1 HLA-DRB1
20	hypersomnia	10.3	HLA-DQB1 HLA-DRB1
21	papilloma	10.3
22	pure red-cell aplasia	10.3	HLA-DRB1 IL2
23	severe hemophilia a	10.3	HLA-DQB1 HLA-DRB1
24	ocular cicatricial pemphigoid	10.3	HLA-DQB1 HLA-DRB1
25	limited scleroderma	10.3	HLA-DRB1 IL2
26	discoid lupus erythematosus	10.2	HLA-DRB1 IFNA2
27	rheumatic fever	10.2	HLA-DRB1 IL2
28	paraneoplastic pemphigus	10.2	HLA-DQB1 HLA-DRB1
29	squamous cell carcinoma	10.2
30	brain glioma	10.2	EGFR HLA-DRB1
31	vogt-koyanagi-harada disease	10.2	HLA-DQB1 HLA-DRB1
32	achalasia, familial esophageal	10.2	HLA-DQA1 HLA-DQB1
33	eosinophilia-myalgia syndrome	10.2	HLA-DQA1 HLA-DRB1
34	sympathetic ophthalmia	10.2	HLA-DQA1 HLA-DRB1
35	laryngitis	10.2
36	congenital toxoplasmosis	10.1	HLA-DQA1 HLA-DQB1
37	cervical dystonia	10.1	HLA-DQA1 HLA-DQB1
38	endometritis	10.1	HLA-DQA1 HLA-DQB1
39	exanthem	10.1	EGFR IL2
40	lymphangioma	10.1	EGFR IFNA2
41	aging	10.1
42	bone inflammation disease	10.1	HLA-DRB1 IL2
43	herpes zoster	10.1	IFNA2 IL2
44	cervical squamous cell carcinoma	10.1	EGFR HLA-DRB1
45	rheumatic heart disease	10.1	HLA-DQA1 HLA-DRB1
46	dermatitis herpetiformis	10.1	HLA-DQA1 HLA-DQB1
47	penile cancer	10.1	EGFR IFNA2
48	microscopic colitis	10.0	HLA-DQB1 HLA-DRB1 IL2
49	graft-versus-host disease	10.0	HLA-DQB1 HLA-DRB1 IL2
50	geographic tongue	10.0	EGFR HLA-DQB1 HLA-DRB1

Graphical network of the top 20 diseases related to Recurrent Respiratory Papillomatosis:

Sources

Symptoms & Phenotypes for Recurrent Respiratory Papillomatosis

Sources

Drugs & Therapeutics for Recurrent Respiratory Papillomatosis

Drugs for Recurrent Respiratory Papillomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cidofovir

Approved

Phase 4,Phase 2

113852-37-2

60613

Synonyms:

({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid

({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid

(2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine

(S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid

(s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid

(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine

(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine

(S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine

(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine

(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid

(S)-HPMPC

[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid

[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid

[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid

1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine

1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine

1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine

1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate

113852-37-2

120362-37-0 (hydrochloride salt)

149394-66-1

AC-1666

AC1L1TLB

AC1Q6C68

AKOS005145721

C8H14N3O6P

CDV

CHEBI:3696

CHEMBL152

CID60613

Cidofovir

Cidofovir (anhydrous)

Cidofovir (Vistide)

Cidofovir anhydrous

Cidofovir Anhydrous

Cidofovirum

DB00369

Forvade

GS 0504

GS 504

GS-0504

GS504

GS-504

HPMPC

HSDB 7115

LS-106432

MolPort-005-935-597

NSC742135

S1516_Selleck

UNII-768M1V522C

Vistide

Vistide, Cidofovir

Anti-Infective Agents

Phase 4,Phase 2

Antiviral Agents

Phase 4,Phase 3,Phase 2

Vaccines

Phase 3,Early Phase 1

Immunoglobulins

Phase 3,Phase 2

Antibodies

Phase 3,Phase 2

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Synonyms:

169590-42-5

184007-95-2

1oq5

4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide

4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE

4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide

AC1L1E6K

AC-4228

AI-525

Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)

BIDD:GT0408

BRD-K02637541-001-02-4

BSPBio_003596

C07589

C105934

C17H14F3N3O2S

CCRIS 8679

CEL

Celebra

Celebrex

Celebrex (TN)

Celebrex, Celebra, Celecoxib

Celecox

Celecoxi

celecoxib

Celecoxib

Célécoxib

Celecoxib (JAN/USAN/INN)

Celecoxib (SC-58635)

Celecoxib [Old RN]

Celecoxib [USAN]

Celecoxibum

Celocoxib

CEP-33222

CHEBI:41423

CHEMBL118

CID2662

cMAP_000027

CPD000550473

D00567

DB00482

DivK1c_000893

Eurocox

FT-0080064

HMS1922G14

HMS2089L18

HMS2093I07

HMS502M15

HSDB 7038

I01-1033

IDI1_000893

KBio1_000893

KBio2_000912

KBio2_002351

KBio2_003480

KBio2_004919

KBio2_006048

KBio2_007487

KBio3_002830

KBio3_003037

KBioGR_000723

KBioGR_002351

KBioSS_000912

KBioSS_002354

LS-31667

Medicoxib

MLS001165684

MLS001195656

MLS001304708

MolPort-002-885-815

NCGC00091455-01

NCGC00091455-02

NCGC00091455-03

NCGC00091455-04

NCI60_041049

NINDS_000893

NSC719627

Onsenal

p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide

P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide

Pfizer brand of celecoxib

S1261_Selleck

SAM002589995

SC 58635

SC-58553, SC-58635

SC58635

SC-58635

SMR000550473

Solexa

SPBio_001512

Spectrum_000432

SPECTRUM1503678

Spectrum2_001576

Spectrum3_001996

Spectrum4_000182

Spectrum5_001324

TL8001323

TPI-336

UNM-0000305813

Xilebao

YM 177

YM177

YM-177

ZINC02570895

Bevacizumab

Approved, Investigational

Phase 2,Phase 1

216974-75-3

Synonyms:

216974-75-3

antiVEGF

anti-VEGF monoclonal antibody

Avastin

Avastin (TN)

bevacizumab

Bevacizumab

Bevacizumab (genetical recombination)

Bevacizumab (genetical recombination) (JAN)

bevacizumab-awwb

D06409

R-435

Pembrolizumab

Approved

Phase 2

1374853-91-4

Vitamin A

Approved, Nutraceutical, Vet_approved

Phase 2

68-26-8, 11103-57-4

445354

Synonyms:

(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol

(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol

(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol

.alpha.lin

.alpha.sterol

.beta.-Retinol

[11,12-3H]-Retinol

11103-57-4

13123-33-6

1341-18-0

1406-67-3

17104-91-5

1rbp

3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol

3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol

3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol

3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer

3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol

4-06-00-04133 (Beilstein Handbook Reference)

53637-36-8

5979-23-7

68-26-8

95144_FLUKA

95144_SIGMA

95146_FLUKA

95146_SIGMA

AC-11701

AC1L9HU3

AC1Q7BU9

ACON

Afaxin

Agiolan

Agoncal

Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol

Alcovit A

alin

All Trans Retinol

All-trans retinol

ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)

all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol

all-trans-retinol

all-trans-Retinol

All-trans-Retinol

all-trans-retinyl alcohol

all-trans-Retinyl alcohol

all-trans-Vitamin A

all-trans-vitamin A alcohol

all-trans-Vitamin A alcohol

all-trans-Vitamin A1

Alphalin

Alphasterol

A-Mulsal

Anatola

Anatola A

Anti-infective vitamin

Antixerophthalmic vitamin

Antixerophthalmisches Vitamin

Aoral

Apexol

Apostavit

Aquasol A Parenteral

Aquasynth

AR-1L3057

A-Sol

Atars

ATAV

Avibon

A-Vi-Pel

Avita

A-Vitan

Avitol

Axerol

Axerophthol

Axerophtholum

Bentavit A

beta-Retinol

BIDD:PXR0102

Biosterol

b-Retinol

BRN 0403040

C00473

C17276

C20H30O

CCRIS 5444

CHEBI:17336

CHEMBL986

Chocola A

CID445354

Cylasphere

D014801

D06543

DB00162

Del-VI-A

Disatabs Tabs

Dofsol

Dohyfral A

EINECS 200-683-7

EINECS 234-328-2

Epiteliol

Hi-A-Vita

HMS1921B04

HMS2092L13

HMS501I08

Homagenets Aoral

Homagenets aorl

HSDB 815

Hydrovit A

IDI1_000486

Lard Factor

LMPR01090001

LPK

LS-1578

M.V.C. 9+3

M.V.I.-12

MLS001066379

MLS001074751

MolPort-001-785-962

Mvc Plus

Myvpack

NCGC00091784-01

NCGC00091784-02

NCGC00091784-03

NCGC00091784-04

NCGC00091784-05

NCGC00091784-06

Nio-A-Let

NSC 122759

NSC122759

Oleovitamin A

Ophthalamin

Plivit A

Prepalin

R7632_SIGMA

Retin-11,12-t2-ol (9CI)

retinol

Retinol

Retinol [INN:BAN]

Retinol solution

Retinol-(cellular-retinol-binding-protein)

Retinol, all-trans- (8CI)

Retinolo

Retinolo [DCIT]

Retinolum

Retinolum [INN-Latin]

Retrovitamin A

Ro-a-vit

Rovimix A 500

SDCCGMLS-0066724.P001

Sehkraft A

SMP2_000102

SMR000112036

Solu-A

SPECTRUM1501203

Spectrum5_000993

Spectrum5_001997

ST057232

Super A

Testavol

Testavol S

Thalasphere

trans-retinol

trans-Retinol

trans-Retinol acid (Vitamin A)

trans-Vitamin A alcohol

tROL

UNII-81G40H8B0T

UNII-G2SH0XKK91

Vaflol

Vafol

Veroftal

Vi-.alpha.

Vi-a

Vi-Alpha

Vi-Dom-A

Vio-A

Vitamin A

Vitamin- A

Vitamin A (Feed)

Vitamin A (USP)

Vitamin A alcohol

Vitamin- A alcohol

Vitamin A alcohol (VAN)

Vitamin- A alcohol solution

Vitamin A cryst

Vitamin A1

Vitamin- A1

Vitamin A1 alcohol

Vitamin A1 alcohol, all trans

Vitamin-?A

Vitamin-?A alcohol

Vitamin-?A alcohol solution

Vitamin-?A1

Vitamine A

Vitaminum A

Vitavel A

Vitavel-A

Vitpex

Vogan

Vogan-Neu

Vogan-nu

Wachstumsvitamin

WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1

ZINC03831417

Zinosan N

Analgesics

Phase 2

Cyclooxygenase 2 Inhibitors

Phase 2

Cyclooxygenase Inhibitors

Phase 2

Analgesics, Non-Narcotic

Phase 2

Angiogenesis Inhibitors

Phase 2,Phase 1

Angiogenesis Modulating Agents

Phase 2,Phase 1

Peripheral Nervous System Agents

Phase 2

Anti-Inflammatory Agents

Phase 2

Anti-Inflammatory Agents, Non-Steroidal

Phase 2

Antirheumatic Agents

Phase 2

Retinol palmitate

Phase 2

Antibodies, Monoclonal

Phase 2

Pharmaceutical Solutions

Phase 2

retinol

Nutraceutical

Phase 2

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 1

1406-16-2

Ergocalciferol

Approved, Nutraceutical

Phase 1

50-14-6

5280793

Synonyms:

(+)-Vitamin D2

(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol

(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol

(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol

(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol

(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol

(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol

(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol

(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol

(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol

22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol

31316-19-5

47768_SUPELCO

4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol

50-14-6

7489-18-1

7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87

8017-28-5

9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol

9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol

9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol

9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol

95220_FLUKA

95220_SIGMA

AC-1355

AC1L1FIE

AC1NQXLH

AC1NS4DE

AC1NS9GI

AC1NSSVD

AC1NWAM3

AC1O5EDK

AC1O6WAM

ACon1_002187

Activated ergosterol

beta-Ol

bmse000510

BPBio1_000418

BSPBio_000380

BSPBio_001974

Buco-D

C05441

C28H44O

Calciferol

Calciferol (TN)

Calciferol (vitamin D2)

CALCIFEROL IN A GELATIN MATRIX

CALCIFEROL, U.S.P.

Calciferolum

Calciferon 2

CHEBI:28934

CHEMBL1536

CID11003810

CID3249

CID5280793

CID5315257

CID5353610

CID5356615

CID5702050

CID6432478

CID6536972

component of Geltabs Vitamin D

Condacaps

Condocaps

Condol

Crtron

Crystallina

D00187

Daral

D-Arthin

Davitamon D

Davitin

DB00153

Decaps

Dee-Osterol

Dee-Ron

Dee-Ronal

Dee-Roual

delta-Arthin

Deltalin

delta-Tracetten

De-rat concentrate

Deratol

Detalup

Diactol

Divit urto

Doral

Drisdol

Drisdol (TN)

D-Tracetten

E5750_SIGMA

EINECS 200-014-9

Ercalciol

ergocalciferol

Ergocalciferol

Ergocalciférol

Ergocalciferol (D2)

Ergocalciferol (JP15/USP)

Ergocalciferol [INN:BAN:JAN]

Ergocalciferol oil

Ergocalciferol: Vitamin D

Ergocalciferolo

Ergocalciferolo [DCIT]

Ergocalciferols

Ergocalciferolum

Ergocalciferolum [INN-Latin]

Ergorone

Ergosterol activated

Ergosterol irradiated

'Ergosterol irradiated'

Ergosterol, irradiated

Ertron

Fortodyl

Geltabs

Geltabs Vitamin D

Haliver

Hi-Deratol

HMS1920K20

HMS2091B19

HMS502I07

HSDB 819

Hyperkil

I05-0022

IDI1_000805

Infron

Irradiated ergosta-5,7,22-trien-3.beta.-ol

Irradiated ergosta-5,7,22-trien-3beta-ol

Irradiated ergosta-5,7,22-trien-3-beta-ol

Irradiated ergosterol

LMST03010001

LMST03010014

LS-3228

MEGxm0_000466

Metadee

Mina D2

MLS001332467

MLS001332468

MolPort-001-740-057

MolPort-001-793-930

MolPort-002-526-645

MolPort-003-666-178

MolPort-006-822-629

Mulsiferol

Mykostin

NCGC00142497-01

NCGC00179579-01

NCGC00179579-02

Novovitamin-D

NSC 62792

NSC62792

Oleovitamin D

Oleovitamin D, Synthetic

Oleovitamin D2

Osteil

Ostelin

Prestwick_554

Prestwick3_000420

Radiostol

Radstein

Radsterin

Rodine C

Rodinec

Shock-ferol

Shock-ferol sterogyl

SMR000857106

Sorex C.R

Sorex C.R.

SPECTRUM1500276

Spectrum5_000666

ST057150

Sterogyl

STOCK1N-53397

Synthetic Vitamin D

UNII-VS041H42XC

Uvesterol D

Uvesterol-D

Vigantol

Vio D

Vio-D

Viostdrol

Viosterol

Viosterol in Oil

vitamin d-2

Vitamin D2

Vitamin- D2

VITAMIN D2

VITAMIN D2 WATER DISPERSABLE U.S.P.

Vitamin-?D2

VITAMIN_D2

Vitamina D2

Vitavel-D

WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ

ZINC04474571

ZINC04629876

Micronutrients

Phase 1

Trace Elements

Phase 1

Vitamins

Phase 1

Ergocalciferols

Phase 1

Bone Density Conservation Agents

Phase 1

Vitamin D2

Nutraceutical

Phase 1

Calciferol

Nutraceutical

Phase 1

3,3'-diindolylmethane

Investigational

1968-05-4

Pepsin A

Protective Agents

Interventional clinical trials:

(show all 20)

#	Name	Status	NCT ID	Phase	Drugs
1	Use of Cidofovir for Recurrent Respiratory Papillomatosis	Completed	NCT00205374	Phase 4	Cidofovir;Placebo
2	Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")	Terminated	NCT00747461	Phase 4
3	4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children	Unknown status	NCT01995721	Phase 3
4	Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis	Active, not recruiting	NCT01375868	Phase 3
5	Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis	Withdrawn	NCT01058317	Phase 2, Phase 3	Propranolol
6	Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis	Completed	NCT00571701	Phase 2	celebrex (celecoxib);placebo
7	A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis	Completed	NCT00038714	Phase 2	SGN-00101
8	Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis	Recruiting	NCT02555800	Phase 2	Bevacizumab;Cidofovir
9	Avelumab for People With Recurrent Respiratory Papillomatosis	Recruiting	NCT02859454	Phase 2	Avelumab
10	Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement	Recruiting	NCT02632344	Phase 2	Pembrolizumab
11	Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)	Completed	NCT01020747	Phase 1	Avastin® (bevacizumab);Saline
12	Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)	Not yet recruiting	NCT02854761	Phase 1	EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
13	Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease	Withdrawn	NCT00733252	Phase 1
14	Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP	Completed	NCT00550914
15	Human Papillomatosis Genotyping of Children in Thailand	Completed	NCT01304966
16	Human Papillomavirus 6/11 in the Lower Airway of Neonates	Completed	NCT00549250
17	Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions	Completed	NCT02217358
18	Recurrent Respiratory Papillomatosis and Extraesophageal Reflux	Recruiting	NCT02592902
19	New Therapy of Laryngeal Papilloma In Children	Terminated	NCT00591305
20	Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis	Withdrawn	NCT00829608	Early Phase 1

Search NIH Clinical Center for Recurrent Respiratory Papillomatosis

Sources

Genetic Tests for Recurrent Respiratory Papillomatosis

Sources

Anatomical Context for Recurrent Respiratory Papillomatosis

MalaCards organs/tissues related to Recurrent Respiratory Papillomatosis:

³⁸

Lung, Bone, T Cells, Testes, Trachea, Spinal Cord

Sources

Publications for Recurrent Respiratory Papillomatosis

Articles related to Recurrent Respiratory Papillomatosis:

(show top 50) (show all 398)

#	Title	Authors	Year
1	A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. ( 29136168 )	Novakovic D....Brotherton J.M.L.	2018
2	A retrospective case control analysis of the efficacy of Gardasil<sup>Ar</sup>vaccination in 28 patients with recurrent respiratory papillomatosis of the larynx. ( 29380936 )	Milner T.D....MacKenzie K.	2018
3	Reply to Fernandez-Bussy et al.: Recurrent Respiratory Papillomatosis and Bevacizumab Treatment. ( 28968137 )	Kalanjeri S....Almeida F.A.	2018
4	Juvenile-Onset Recurrent Respiratory Papillomatosis: The Benefits of Quadrivalent Human Papillomavirus Vaccination Continue to Accrue. ( 29136167 )	Donovan B....Callander D.	2018
5	Recurrent Respiratory Papillomatosis and Bevacizumab Treatment. ( 28968150 )	Fernandez-Bussy S....Burotto M.	2018
6	Recurrent respiratory papillomatosis with lung and chest wall involvement: A rare complication in an adolescent. ( 28233516 )	RodrA-guez H....Monaje M.	2017
7	The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis. ( 28940446 )	Ahn J....Best S.R.A.	2017
8	Treatment With Quadrivalent Human Papillomavirus Vaccine for Juvenile-Onset Recurrent Respiratory Papillomatosis: Case Report and Review of the Literature. ( 28992265 )	Katsuta T....Feemster K.A.	2017
9	Recurrent respiratory papillomatosis (RRP)-time for a reckoning? ( 28894838 )	Kin Cho Goon P....Sudhoff H.	2017
10	Therapeutic use of the HPV vaccine in Recurrent Respiratory Papillomatosis: A case report. ( 28109479 )	Sullivan C....Mouzakes J.	2017
11	Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. ( 28231366 )	Meacham R.K....Thompson J.W.	2017
12	PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis. ( 28576522 )	Liu T....Hartnick C.	2017
13	Enhanced TH2-like peripheral adaptive immune responses in Juvenile-onset Recurrent Respiratory Papillomatosis (JORRP). ( 28860041 )	Xiao Y....Wang J.	2017
14	Quality and readability assessment of websites related to recurrent respiratory papillomatosis. ( 28233911 )	San Giorgi M.R.M....Dikkers F.G.	2017
15	Human Papillomavirus (HPV) Genotype Distribution in Patients with Recurrent Respiratory Papillomatosis (RRP) in Iran ( 28749631 )	Eftekhaar N.S....Keyvani H.	2017
16	HLA-DRB1 and HLA-DQB1 alleles in Chinese Han patients with Juvenile-Onset recurrent respiratory papillomatosis. ( 29106857 )	Zhao J....Ni X.	2017
17	Recurrent Respiratory Papillomatosis, more than two entities. ( 29293985 )	San Giorgi M.R.M....Dikkers F.G.	2017
18	Recurrent respiratory papillomatosis in a parturient presenting for cesarean delivery. ( 28347573 )	Segna K.G....Spiegel J.R.	2017
19	Quality of life of young patients with recurrent respiratory papillomatosis. ( 28193306 )	MontaA+o-VelA!zquez B.B....JA!uregui-Renaud K.	2017
20	Age of diagnosis, incidence and prevalence of recurrent respiratory papillomatosis-A South African perspective. ( 29054106 )	Seedat R.Y....Schall R.	2017
21	Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey. ( 28657692 )	Best S.R....Zur K.B.	2017
22	Treatment outcomes of recurrent respiratory papillomatosis : Retrospective analysis of juvenile and adult cases. ( 28840259 )	Papaioannou V.A....Arens C.	2017
23	Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases. ( 28757601 )	Bedoya A....Shofer S.	2017
24	Recurrent respiratory papillomatosis: A state-of-the-art review. ( 28427542 )	Fortes H.R....Marchiori E.	2017
25	Lymphocyte profile and cytokine mRNA expression in peripheral blood mononuclear cells of patients with recurrent respiratory papillomatosis suggest dysregulated cytokine mRNA response and impaired cytotoxic capacity. ( 28805308 )	Holm A....Olofsson K.	2017
26	Laryngeal distribution of recurrent respiratory papillomatosis in a previously untreated cohort. ( 28714564 )	Benedict P.A....Branski R.C.	2017
27	A case of video-assisted thoracoscopic resection of malignant transformation of pulmonary recurrent respiratory papillomatosis. ( 28523179 )	Dominguez D.A....Velotta J.B.	2017
28	In-office vs. operating room procedures for recurrent respiratory papillomatosis. ( 28489241 )	Miller A.J....Gardner G.M.	2017
29	Associations of FoxP3 gene polymorphisms with severe recurrent respiratory papillomatosis in Korean patients. ( 28298239 )	Kwon T.K....Song E.Y.	2017
30	Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report. ( 28977096 )	Maunsell R....Bellomo-BrandALo M.A.	2017
31	Intersurgical interval increased with use of quadrivalent human papillomavirus vaccine (Gardasil) in a pediatric patient with recurrent respiratory papillomatosis: A case report. ( 27863633 )	Baumanis M.M....Elmaraghy C.A.	2016
32	Prevalence and management of Recurrent Respiratory Papillomatosis (RRP) in the UK: cross sectional study. ( 27208548 )	Donne A....Powell S.	2016
33	Quality of life of patients with recurrent respiratory papillomatosis. ( 27861969 )	San Giorgi M.R....Dikkers F.G.	2016
34	Determination of the complete genome and functional analysis of HPV6 isolate VBD19/10 from a patient with aggressive recurrent respiratory papillomatosis. ( 26931553 )	Seedat R.Y....Burt F.J.	2016
35	Validation of the Distress Thermometer and Problem List in Patients with Recurrent Respiratory Papillomatosis. ( 27600632 )	San Giorgi M.R....Dikkers F.G.	2016
36	Office-Based vs Traditional Operating Room Management of Recurrent Respiratory Papillomatosis: Impact of Patient Characteristics and Disease Severity. ( 27658005 )	Tatar E.A.8....Merati A.L.	2016
37	Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis. ( 26968061 )	Hermann J.S....Nagata Pignatari S.S.	2016
38	Intralesional cidofovir injection for recurrent respiratory papillomatosis in Japan. ( 26860235 )	Murono S....Yoshizaki T.	2016
39	Is recurrent respiratory papillomatosis a manageable or curable disease? ( 26608928 )	Kim H.T....Baizhumanova A.S.	2016
40	Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis. ( 27188508 )	Tjon Pian Gi R.E....Dikkers F.G.	2016
41	Laryngopharyngeal reflux and herpes simplex virus type 2 are possible risk factors for adult-onset recurrent respiratory papillomatosis (prospective case-control study). ( 27759910 )	FormA!nek M....ZelenA-k K.	2016
42	Impaired T Cell-dependent Humoral Immune Response Associated with Juvenile-onset Recurrent Respiratory Papillomatosis Progression. ( 27821867 )	Wu X....Ni X.	2016
43	Safety of paediatric day-stay laryngeal surgery for recurrent respiratory papillomatosis. ( 26857327 )	Gruber M....Mahadevan M.	2016
44	The association between gastroesophageal reflux disease and recurrent respiratory papillomatosis: A systematic review. ( 27113025 )	San Giorgi M.R....Dikkers F.G.	2016
45	Response to letter to Editor: "The clinical course of recurrent respiratory papillomatosis after the use of cidofovir is influenced by multiple factors" by Michel R. M. San Giorgi et al. ( 27654254 )	Grasso M....Lawson G.	2016
46	Multidimensional vocal assessment after laser treatment for recurrent respiratory papillomatosis. ( 27515839 )	Kono T....Ogawa K.	2016
47	Juvenile recurrent respiratory papillomatosis: 10-year audit and Australian prevalence estimates. ( 27074766 )	Novakovic D....Brotherton J.M.	2016
48	Differences in Transcriptional Activity of Human Papillomavirus Type 6 Molecular Variants in Recurrent Respiratory Papillomatosis. ( 26151558 )	Measso do Bonfim C....Sichero L.	2015
49	Nucleotide and phylogenetic analysis of human papillomavirus type 11 isolated from juvenile-onset recurrent respiratory papillomatosis in China. ( 26369639 )	Xiao Y....Yang M.	2015
50	Molecular subtypification of human papillomavirus in male adult individuals with recurrent respiratory papillomatosis. ( 25906915 )	GarcA-a-Romero C.S....Coral-VA!zquez R.M.	2015

Sources

Genes for Recurrent Respiratory Papillomatosis

Genes related to Recurrent Respiratory Papillomatosis (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Implication
1	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	18.56	GeneCards inferred via : Publications (show sections)
2	HLA-DQB1	Major Histocompatibility Complex, Class II, DQ Beta 1	Protein Coding	18.46	GeneCards inferred via : Publications (show sections)
3	IL2	Interleukin 2	Protein Coding	18.21	GeneCards inferred via : Publications (show sections)
4	EGFR	Epidermal Growth Factor Receptor	Protein Coding	18.01	GeneCards inferred via : Publications (show sections)
5	HLA-DQA1	Major Histocompatibility Complex, Class II, DQ Alpha 1	Protein Coding	17.66	GeneCards inferred via : Publications (show sections)
6	CD274	CD274 Molecule	Protein Coding	17.66	GeneCards inferred via : Publications (show sections)
7	IFNA2	Interferon Alpha 2	Protein Coding	17.66	GeneCards inferred via : Publications (show sections)

Sources

Variations for Recurrent Respiratory Papillomatosis

Sources

Expression for Recurrent Respiratory Papillomatosis

Search GEO for disease gene expression data for Recurrent Respiratory Papillomatosis.

Sources

Pathways for Recurrent Respiratory Papillomatosis

Pathways related to Recurrent Respiratory Papillomatosis according to GeneCards Suite gene sharing:

(show all 35)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶² Show member pathways Immune System ⁶² Neutrophil degranulation ⁶²	13.73	CD274 EGFR HLA-DQA1 HLA-DQB1 HLA-DRB1 IFNA2
2	GPCR Pathway ⁶⁰ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁰ Estrogen Pathway ⁶⁰ NFAT in Immune Response ⁶⁰ P2Y Receptor Signaling ⁶⁰ Pancreatic Adenocarcinoma ⁶⁰ Paxillin Interactions ⁶⁰ Ras Pathway ⁶⁰	13.43	EGFR HLA-DQA1 HLA-DQB1 HLA-DRB1 IL2
3	Class I MHC mediated antigen processing and presentation ⁶² Show member pathways Adaptive Immune System ⁶² Antigen processing- Ubiquitination and Proteasome degradation ⁶²	13.2	CD274 EGFR HLA-DQA1 HLA-DQB1 HLA-DRB1
4	Cytokine Signaling in Immune system ⁶² Show member pathways Signaling by Interleukins ⁶²	13.04	EGFR HLA-DQA1 HLA-DQB1 HLA-DRB1 IFNA2 IL2
5	IL-2 Pathway ⁶⁰ Show member pathways ErbB Family Pathway ⁶⁰ ErbB2-ErbB3 Heterodimers ⁶⁰ ErbB4 Pathway ⁶⁰ Growth Hormone Signaling ⁶⁰ HMGB1 Pathway ⁶⁰ IL-4 Pathway ⁶⁰ LPS Stimulated MAPK Signaling ⁶⁰ PACAP Signaling ⁶⁰ PI3K Signaling in B-Lymphocyte ⁶⁰ Prolactin Signaling ⁶⁰ Thrombopoietin Pathway ⁶⁰ TREM1 Pathway ⁶⁰ UVC-Induced MAPK Signaling ⁶⁰	12.98	EGFR HLA-DQA1 HLA-DQB1 HLA-DRB1 IL2
6	Actin Nucleation by ARP-WASP Complex ⁶⁰ Show member pathways Actin Nucleation and Branching ⁶⁰ CDC42 Pathway ⁶⁰ RhoA Pathway ⁶⁰	12.77	EGFR HLA-DQA1 HLA-DQB1 HLA-DRB1
7	Allograft rejection ¹ ³⁶ Show member pathways Antigen processing and presentation ³⁶ Asthma ³⁶ Autoimmune thyroid disease ³⁶ CTL Mediated Apoptosis ⁶⁰ Graft-versus-host disease ³⁶ Intestinal immune network for IgA production ³⁶ THC Differentiation Pathway ⁶⁰ Type I diabetes mellitus ³⁶ Viral myocarditis ³⁶	12.46	HLA-DQA1 HLA-DQB1 HLA-DRB1 IFNA2 IL2
8	Immune response NFAT in immune response ²¹ Show member pathways Immune response CD28 signaling ²¹ Immune response ICOS pathway in T-helper cell ²¹ Immune response T cell receptor signaling pathway ²¹	12.43	HLA-DQA1 HLA-DQB1 HLA-DRB1 IL2
9	Th17 cell differentiation ³⁶ Show member pathways IL-22 Pathway ⁶⁰ Immune response IL-22 signaling pathway ²¹ Inflammatory bowel disease (IBD) ³⁶ Th1 and Th2 cell differentiation ³⁶	12.39	HLA-DQA1 HLA-DQB1 HLA-DRB1 IL2
10	Influenza A ³⁶ Show member pathways Herpes simplex infection ³⁶ Measles ³⁶	12.35	HLA-DQA1 HLA-DQB1 HLA-DRB1 IFNA2 IL2
11	Interferon gamma signaling ⁶² Show member pathways Interferon Signaling ⁶² Regulation of IFNG signaling ⁶²	12.33	HLA-DQA1 HLA-DQB1 HLA-DRB1 IFNA2
12	HTLV-I infection ³⁶	12.2	HLA-DQA1 HLA-DQB1 HLA-DRB1 IL2
13	TCR signaling (REACTOME) ⁶² Show member pathways Downstream TCR signaling ⁶²	12.17	HLA-DQA1 HLA-DQB1 HLA-DRB1
14	Jak-STAT signaling pathway (KEGG) ³⁶ Show member pathways B-Cell Development ⁶⁰ IL-7 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶¹ Interleukin-19, 20, 22, 24 ⁶² Jak/STAT Signaling Pathway ⁶¹	12.17	EGFR IFNA2 IL2
15	ICos-ICosL Pathway in T-Helper Cell ⁶⁰ Show member pathways Calcium Mediated T-Cell Apoptosis ⁶⁰ CD28 Signaling in T-Helper Cell ⁶⁰	12.16	HLA-DQA1 HLA-DQB1 HLA-DRB1 IL2
16	Epstein-Barr virus infection ³⁶	12.12	HLA-DQA1 HLA-DQB1 HLA-DRB1
17	Toxoplasmosis ³⁶ Show member pathways Leishmaniasis ³⁶	12.07	HLA-DQA1 HLA-DQB1 HLA-DRB1
18	Phagosome ³⁶	11.97	HLA-DQA1 HLA-DQB1 HLA-DRB1
19	Tuberculosis ³⁶	11.96	HLA-DQA1 HLA-DQB1 HLA-DRB1 IFNA2
20	CD28 co-stimulation ⁶² Show member pathways Activation of AKT2 ⁶² CD28 dependent PI3K/Akt signaling ⁶² CD28 dependent Vav1 pathway ⁶² Costimulation by the CD28 family ⁶² VEGFR2 mediated vascular permeability ⁶²	11.91	CD274 HLA-DQA1 HLA-DQB1 HLA-DRB1
21	MHC class II antigen presentation ⁶²	11.77	HLA-DQA1 HLA-DQB1 HLA-DRB1
22	Hematopoietic cell lineage ³⁶	11.73	HLA-DQA1 HLA-DQB1 HLA-DRB1
23	Jak-Stat Signaling Pathway (sino) ⁶³	11.69	EGFR IFNA2 IL2
24	Rheumatoid arthritis ³⁶	11.69	HLA-DQA1 HLA-DQB1 HLA-DRB1
25	G-protein signaling N-RAS regulation pathway ²¹ Show member pathways Immune response Antigen presentation by MHC class II ²¹	11.57	HLA-DQA1 HLA-DQB1 HLA-DRB1
26	CTLA4 Signaling ⁶⁰	11.55	HLA-DQA1 HLA-DQB1 HLA-DRB1
27	Regulation of Telomerase ¹	11.48	EGFR IL2
28	Staphylococcus aureus infection ³⁶	11.43	HLA-DQA1 HLA-DQB1 HLA-DRB1
29	S-1P Stimulated Signaling ⁶⁰	11.43	EGFR HLA-DQA1 HLA-DQB1 HLA-DRB1
30	Cell adhesion molecules (CAMs) ³⁶	11.42	CD274 HLA-DQA1 HLA-DQB1 HLA-DRB1
31	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.37	EGFR IL2
32	Aryl Hydrocarbon Receptor Pathway ¹	11.34	EGFR IL2
33	Cytokines and Inflammatory Response ¹	11.13	HLA-DRB1 IL2
34	IL12 signaling mediated by STAT4 ¹	11.09	HLA-DRB1 IL2
35	Translocation of ZAP-70 to Immunological synapse ⁶² Show member pathways Generation of second messenger molecules ⁶² PD-1 signaling ⁶² Phosphorylation of CD3 and TCR zeta chains ⁶²	10.96	CD274 HLA-DQA1 HLA-DQB1 HLA-DRB1

Sources

GO Terms for Recurrent Respiratory Papillomatosis

Cellular components related to Recurrent Respiratory Papillomatosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	Golgi membrane	GO:0000139	9.76	EGFR HLA-DQA1 HLA-DQB1 HLA-DRB1
2	lysosomal membrane	GO:0005765	9.65	HLA-DQA1 HLA-DQB1 HLA-DRB1
3	trans-Golgi network membrane	GO:0032588	9.61	HLA-DQA1 HLA-DQB1 HLA-DRB1
4	endocytic vesicle membrane	GO:0030666	9.58	HLA-DQA1 HLA-DQB1 HLA-DRB1
5	endosome membrane	GO:0010008	9.56	EGFR HLA-DQA1 HLA-DQB1 HLA-DRB1
6	ER to Golgi transport vesicle membrane	GO:0012507	9.54	HLA-DQA1 HLA-DQB1 HLA-DRB1
7	transport vesicle membrane	GO:0030658	9.5	HLA-DQA1 HLA-DQB1 HLA-DRB1
8	clathrin-coated endocytic vesicle membrane	GO:0030669	9.33	HLA-DQA1 HLA-DQB1 HLA-DRB1
9	integral component of lumenal side of endoplasmic reticulum membrane	GO:0071556	9.13	HLA-DQA1 HLA-DQB1 HLA-DRB1
10	MHC class II protein complex	GO:0042613	8.8	HLA-DQA1 HLA-DQB1 HLA-DRB1

Biological processes related to Recurrent Respiratory Papillomatosis according to GeneCards Suite gene sharing:

(show all 16)

#	Name	GO ID	Score	Top Affiliating Genes
1	cell surface receptor signaling pathway	GO:0007166	9.69	CD274 EGFR IFNA2
2	T cell receptor signaling pathway	GO:0050852	9.63	HLA-DQA1 HLA-DQB1 HLA-DRB1
3	antigen processing and presentation of exogenous peptide antigen via MHC class II	GO:0019886	9.61	HLA-DQA1 HLA-DQB1 HLA-DRB1
4	positive regulation of inflammatory response	GO:0050729	9.56	EGFR IL2
5	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.55	IFNA2 IL2
6	immune response	GO:0006955	9.55	CD274 HLA-DQA1 HLA-DQB1 HLA-DRB1 IL2
7	positive regulation of T cell proliferation	GO:0042102	9.54	CD274 IL2
8	interferon-gamma-mediated signaling pathway	GO:0060333	9.54	HLA-DQA1 HLA-DQB1 HLA-DRB1
9	negative regulation of T cell proliferation	GO:0042130	9.52	CD274 HLA-DRB1
10	positive regulation of phosphorylation	GO:0042327	9.49	EGFR IFNA2
11	negative regulation of interferon-gamma production	GO:0032689	9.48	CD274 HLA-DRB1
12	antigen processing and presentation	GO:0019882	9.43	HLA-DQA1 HLA-DQB1 HLA-DRB1
13	humoral immune response mediated by circulating immunoglobulin	GO:0002455	9.4	HLA-DQB1 HLA-DRB1
14	immunoglobulin production involved in immunoglobulin mediated immune response	GO:0002381	9.32	HLA-DQB1 HLA-DRB1
15	antigen processing and presentation of peptide or polysaccharide antigen via MHC class II	GO:0002504	9.13	HLA-DQA1 HLA-DQB1 HLA-DRB1
16	T cell costimulation	GO:0031295	8.92	CD274 HLA-DQA1 HLA-DQB1 HLA-DRB1

Molecular functions related to Recurrent Respiratory Papillomatosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	peptide antigen binding	GO:0042605	9.13	HLA-DQA1 HLA-DQB1 HLA-DRB1
2	MHC class II receptor activity	GO:0032395	8.8	HLA-DQA1 HLA-DQB1 HLA-DRB1

Sources

Sources for Recurrent Respiratory Papillomatosis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ ExPASy

¹⁷ FDA Approved Drugs

¹⁸ FMA

¹⁹ GeneAnalytics

²⁰ GeneCards

²¹ GeneGo (Thomson Reuters)

²² GeneHancer via GeneCards

²³ GeneReviews

²⁴ Genetics Home Reference

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HGMD

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ MalaCards

³⁹ MedGen

⁴⁰ MedlinePlus

⁴¹ MeSH

⁴² MESH via Orphanet

⁴³ MGI

⁴⁴ NCBI Bookshelf

⁴⁵ NCI

⁴⁶ NCIt

⁴⁷ NDF-RT

⁴⁸ NIH Clinical Center

⁴⁹ NIH Rare Diseases

⁵⁰ NINDS

⁵¹ Novoseek

⁵² Novus Biologicals

⁵³ OMIM

⁵⁴ OMIM via Orphanet

⁵⁵ Orphanet

⁵⁶ PathCards

⁵⁷ PharmGKB

⁵⁸ PubMed

⁵⁹ PubMed Health

⁶⁰ QIAGEN

⁶¹ R&D Systems

⁶² Reactome

⁶³ Sino Biological

⁶⁴ SNOMED-CT

⁶⁵ SNOMED-CT via HPO

⁶⁶ SNOMED-CT via Orphanet

⁶⁷ TGDB

⁶⁸ Tocris

⁶⁹ UMLS

⁷⁰ UMLS via Orphanet

⁷¹ UniProtKB/Swiss-Prot

⁷² Wikipedia